Get started
Author

Alex John Liu

Observed names: Alex J Liu, Alex J. Liu
ORCID: 0000-0002-0019-1906
Observed ORCID: 0000-0002-0019-1906
OpenAlex ID: A5084698652
The Role of Maintenance Strategies in Metastatic Colorectal Cancer
2019 · Mohamad Bassam Sonbol, Luke J. Mountjoy, et al. · JAMA Oncology · 113
PDF
Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors
2021 · Alex J. Liu, Benjamin E. Ueberroth, et al. · The Oncologist · 51
PDF
Outcomes on anti‐VEGFR ‐2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma
2021 · Lionel A. Kankeu Fonkoua, Sakti Chakrabarti, et al. · International Journal of Cancer · 26
Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms
2021 · Jennifer J. Gile, Alex J. Liu, et al. · Pancreas · 16
Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma
2021 · Pedro Luiz Serrano Uson Junior, Alex J. Liu, et al. · Chinese Clinical Oncology · 14
PDF
The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases
2022 · Alex J. Liu, Heidi E. Kosiorek, et al. · The Prostate · 13
Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options
2020 · Benjamin E. Ueberroth, Alex J. Liu, et al. · Clinical Colorectal Cancer · 13
Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis
2024 · Rodrigo Fonseca, Alex J. Liu, et al. · Blood Neoplasia · 8
Osteoclast-Like Giant Cell Tumors of the Pancreas
2021 · Benjamin E. Ueberroth, Alex J. Liu, et al. · Pancreas · 7
Currarino Syndrome
2020 · Alex J. Liu, Thorvardur R. Halfdanarson, et al. · Pancreas · 7
Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA).
2020 · Lionel Aurelien Kankeu Fonkoua, Sakti Chakrabarti, et al. · Journal of Clinical Oncology · 6
Prevalence of adverse events following bispecific antibody therapy in non-Hodgkin lymphoma: A meta-analysis.
2024 · Alex John Liu, Rodrigo Fonseca, et al. · Journal of Clinical Oncology · 2
PDF
Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA).
2020 · Lionel Aurelien Kankeu Fonkoua, Sakti Chakrabarti, et al. · Journal of Clinical Oncology · 2
Co-occurring alterations across molecular pathways in metastatic colorectal cancer (mCRC).
2022 · Alex John Liu, Daniel Walden, et al. · Journal of Clinical Oncology · 1
Genomic predictors of benefit from checkpoint inhibition in neuroendocrine carcinoma.
2022 · Patrick Walsh McGarrah, Jennifer Gile, et al. · Journal of Clinical Oncology
Changes in prescribing patterns in stage III colon cancer (CC) since the IDEA collaboration.
2022 · Daniel Walden, Fang-Shu Ou, et al. · Journal of Clinical Oncology
Osteoclast-like giant cell tumors of the pancreas: Clinical characteristics, genetic testing, and treatment modalities.
2020 · Benjamin Edward Ueberroth, Alex John Liu, et al. · Journal of Clinical Oncology
The impact of genetic mutations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
2020 · Alex John Liu, Heidi E. Kosiorek, et al. · Journal of Clinical Oncology
Anorectal neuroendocrine carcinoma (NEC): Patient characteristics and treatment outcomes.
2020 · Benjamin Edward Ueberroth, Alex John Liu, et al. · Journal of Clinical Oncology
Treatment outcomes of well-differentiated high-grade (G3) neuroendocrine tumors.
2020 · Alex John Liu, Benjamin Edward Ueberroth, et al. · Journal of Clinical Oncology
Correlative analysis of circulating tumor (ct) DNA and tumor mutational analysis (TMA) in patients with advanced pancreatobilliary malignancies (PBM).
2018 · Hani M. Babiker, Alex John Liu, et al. · Journal of Clinical Oncology
Works count: 21
Citation count: 279
H-index: 8
I10-index: 7
Year
Topic
Type